750,000 Shares in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Purchased by Toronto Dominion Bank

Toronto Dominion Bank acquired a new position in Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 750,000 shares of the company's stock, valued at approximately $1,770,000. Toronto Dominion Bank owned about 1.41% of Milestone Pharmaceuticals at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Cubist Systematic Strategies LLC bought a new position in Milestone Pharmaceuticals during the fourth quarter worth $73,000. Jones Financial Companies Lllp boosted its stake in Milestone Pharmaceuticals by 1,000.0% during the fourth quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company's stock worth $26,000 after buying an additional 10,000 shares in the last quarter. Boxer Capital Management LLC acquired a new stake in Milestone Pharmaceuticals during the fourth quarter worth $729,000. Virtu Financial LLC acquired a new stake in Milestone Pharmaceuticals during the fourth quarter worth $170,000. Finally, XTX Topco Ltd acquired a new stake in Milestone Pharmaceuticals during the fourth quarter worth $80,000. 86.18% of the stock is currently owned by institutional investors and hedge funds.

Milestone Pharmaceuticals Price Performance

Shares of NASDAQ:MIST traded up $0.05 on Thursday, hitting $1.57. The stock had a trading volume of 292,886 shares, compared to its average volume of 904,730. Milestone Pharmaceuticals Inc. has a twelve month low of $0.63 and a twelve month high of $2.75. The company has a debt-to-equity ratio of 2.18, a quick ratio of 15.40 and a current ratio of 15.40. The firm's 50 day moving average price is $1.16 and its 200-day moving average price is $1.69. The company has a market capitalization of $83.67 million, a price-to-earnings ratio of -1.93 and a beta of 0.86.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.12). On average, equities research analysts predict that Milestone Pharmaceuticals Inc. will post -0.62 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. TD Securities downgraded shares of Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, April 1st. TD Cowen downgraded shares of Milestone Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, April 1st. Cowen downgraded shares of Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, April 1st. Finally, HC Wainwright reiterated a "buy" rating and set a $25.00 price target on shares of Milestone Pharmaceuticals in a research note on Friday, March 28th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $17.00.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.